Mark Frohlich
Company: Indapta Therapeutics
Job title: CEO
Seminars:
Chair’s Opening Remarks 8:25 am
day: Day 2 AM
Case Study: Key Considerations for Developing a Combination Product 9:00 am
Discussing the development of g-NK cell therapy with antibody combinations for NHL and AML Understanding how to navigate regulations and patient treatment procedures with multiple treatment regiments Highlighting positive clinical data reinforcing the rationale behind a combination approachRead more
day: Day 2 AM
Panel Discussion: Evaluating Clinical Potential of Different NK Subtypes 2:30 pm
Discuss how different NK subtypes perform against various cancer types and disease models How do different NK phenotypes influence therapeutic outcomes? Is it best to have a homogenous or heterogenous NK product?Read more
day: Day 2 - Track B - PM
Maximizing NK Expansion for a Robust & Effective Scale-Up of an Allogeneic Product 11:15 am
day: Day 2 - Track B- AM